

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) A method for the therapeutic treatment of a carcinoma ~~caner~~ in a mammal wherein (i) the mammal comprises a mutated fibroblast growth factor receptor-4 (FGFR-4) protein, and (ii) the mutated FGFR-4 protein comprises the amino acid sequence of SEQ ID NO: 9 except that glycine at position 388 of SEQ ID NO: 9 has been substituted with arginine, at least one point mutation in the transmembrane domain of FGFR-4 that substitutes a hydrophilic amino acid for a hydrophobic amino acid, which method comprises administering to the mammal an effective amount of at least one inhibitor of the mutated FGFR-4, wherein the carcinoma ~~caner~~ in the mammal is treated.
2. (Canceled)
3. (Currently Amended) The method of claim 1, wherein said carcinoma ~~caner~~ is breast cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, or uterine cancer.
4. (Original) The method of claim 1, wherein said inhibitor is a kinase-inactive receptor.

5.-12. (Canceled)

13. (Currently Amended) The method of claim 1, wherein the mutated FGFR-4 protein is encoded by a FGFR-4 gene comprising mutation is a germ line mutation.

14.-29. (Canceled)